Amicus Therapeutics Inc (NASDAQ: FOLD) has reported a loss for its first fiscal quarter (ending March 31) of $-0.16 versus a loss $-0.18 for the same period a year ago. Relative to the consensus estimate of $0.01, this was a shortfall of $-0.17. For the latest four quarters through March 31, E.P.S. were $-0.49 compared to $-0.70 a year ago.
Recent Price Action
Amicus Therapeutics Inc (NASDAQ: FOLD) stock closed at $9.48 on 5/9/24 after a large decline of -6.5%. Moreover, exceptionally high trading volume at 237% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months and has declined -9.1% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, FOLD is expected to continue to be a major Value Builder.
Amicus Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Amicus Therapeutics has a poor Power Rating of 27 and a very low Appreciation Score of 13, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment